Other · developed by Sunshine Lake Pharma Co.
HEC-921 is an agent given by intravenous infusion and studied in advanced malignant solid tumors.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07824934 | Phase 1 | Advanced Malignant Solid Tumors | Recruiting | SBFM |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Advanced Malignant Solid Tumors
Updated Nov 1, 2026. Something wrong or missing? Report it on the SBFM page.
See SBFM's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
SBFM catalysts and pipeline →